Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Other Accumulated Expenses (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Other Accumulated Expenses for 12 consecutive years, with $4.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses fell 30.62% year-over-year to $4.4 million, compared with a TTM value of $4.4 million through Dec 2025, down 30.62%, and an annual FY2025 reading of $4.4 million, down 30.62% over the prior year.
  • Other Accumulated Expenses was $4.4 million for Q4 2025 at Fate Therapeutics, up from $3.9 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $19.2 million in Q4 2022 and bottomed at $3.9 million in Q3 2025.
  • Average Other Accumulated Expenses over 5 years is $9.9 million, with a median of $8.4 million recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses surged 183.19% in 2021, then crashed 63.72% in 2025.
  • Year by year, Other Accumulated Expenses stood at $11.7 million in 2021, then soared by 63.75% to $19.2 million in 2022, then tumbled by 57.66% to $8.1 million in 2023, then dropped by 21.67% to $6.4 million in 2024, then plummeted by 30.62% to $4.4 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for FATE at $4.4 million in Q4 2025, $3.9 million in Q3 2025, and $4.9 million in Q2 2025.